论文标题
通过光学透射显微镜检查组织微阵列(TMA)的分形维度分析来检测癌症阶段
Detection of cancer stages through fractal dimension analysis of tissue microarrays (TMA) via optical transmission microscopy
论文作者
论文摘要
组织是由于其自相似结构而分形的,并且分形维度随着癌症等疾病等异常而变化。使用透射显微镜对薄片组织的光学成像可以产生与其折射率成正比的强度分布模式,该模式代表组织的质量密度分布模式。通过分析这种质量密度分布来计算组织的分形维度,并随着癌变的发展而增加。本文探讨了使用这种定量方法分析分析来创建标准化准确的癌症诊断测试和分期的生存能力,从而减少了困扰当前测试方法的问题。大多数最致命的癌症的共同点是它们的杀伤力是因为难以在早期正确诊断它们或准确的晚期阶段。这种困难可能是由于器官的物理位置引起的,导致它们很难获得,并且直到几乎没有治疗的希望后,才缺乏明显的症状。为了研究这些致命的癌症中的一些,分析了包含多个核心和胰腺,乳腺癌,结肠癌和前列腺癌阶段的多个核心和阶段的市售石蜡嵌入式组织微阵列(TMA)样品。不同TMA样品的分形维度能够正确区分每个癌症的不同阶段,从而增加了将来创建标准化系统以提高诊断准确性的可能性。
Tissues are fractal due to its self-similar structure, and the fractal dimension change with the abnormalities such as in disease like cancer. The optical imaging of thin slices of tissue using transmission microscopy can produce an intensity distribution pattern proportional to its refractive index which represents the mass density distribution pattern of the tissues. The fractal dimension of tissue is calculated by analyzing this mass density distribution and is known to increase with the progression of carcinogenesis. This paper explores the viability of using this quantitative approach of fractal dimension analysis to create a standardized accurate cancer diagnosis test and staging which reduces the issues plaguing current testing methods. A commonality for most of the deadliest cancers is their lethality due to the difficulty in properly diagnosing them in the early stages or accurate late staging. This difficulty can arise from the physical location of the organ causing them to be hard to access and the lack of noticeable symptoms until the late stages when there is almost no hope of treatment. To study some of these deadly cancers, commercially available paraffin embedded tissue microarray (TMA) samples containing multiple cores of different cases and stages of Pancreatic, Breast, Colon, and Prostate cancer are analyzed. The fractal dimension of different TMA samples is able to correctly differentiate between the different stages of each cancer, raising the possibility of a standardized system being created to increase diagnosis accuracy in the future.